As CEO Todd Zavodnick put it: A lot of patients are being undertreated and we believe this market is massive. #Biotech #AllergyInnovation #Immunology #LifeSciences #FundingNews To view or add a comment, sign in Improvement of the therapeutic management of allergic patients in Europe An expert think tank's position paper on allergen immunotherapy To view or add a comment, sign in Yuhan Corporation's novel allergy drug lesigercept gains IND approval from MFDS for Phase 2 clinical trials - 12-week treatment for 150 patients with chronic spontaneous urticaria - Study to confirm safety, efficacy, and clinical benefits in an expanded patient cohort in Asia and Europe Yuhan Corporation announced on October 15 that it received approval from the Ministry of Food and Drug Safety (MFDS) on October 14 for its Phase 2 clinical trial plan (IND) for lesigercept (development code YH35324). Lesigercept is a novel anti-Immunoglobulin E (IgE) Fc fusion protein drug designed to alleviate allergic symptoms through a dual mechanism of action, by binding to and eliminating both free IgE and IgE receptor alpha (FcRI) autoantibodies present in the bloodstream
Moreover, regional differences are pronounced, with the lowest prevalence of BPH observed in the central and southwestern populations, whereas the highest rates are found in the northwestern regions [43, 44]
doi: 10.4049/jimmunol.1003613 88 MuriJKopfM
Overexpression of sucrose phosphate synthase enhanced sucrose content and Biomass production in transgenic sugarcane
Made in the USA in an FDA-registered, GMP-certified facility Certified organic by MOSA Non-GMO Cruelty-free
The TUE Program is a rigorous and necessary part of elite sport and has overwhelming acceptance from athletes, physicians, and anti-doping stakeholders
